These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1141 related items for PubMed ID: 31601267
1. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW. Alzheimers Res Ther; 2019 Oct 10; 11(1):83. PubMed ID: 31601267 [Abstract] [Full Text] [Related]
2. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, Skogseth R, Minthon L, Aarsland D. J Neurol Neurosurg Psychiatry; 2011 Feb 10; 82(2):160-4. PubMed ID: 21047883 [Abstract] [Full Text] [Related]
3. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies. Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, Heitz C, Demuynck C, Gabel A, Martin-Hunyadi C, Blanc F. J Alzheimers Dis; 2016 Feb 10; 51(4):1069-83. PubMed ID: 26923009 [Abstract] [Full Text] [Related]
4. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer's disease. de Oliveira FF, Miraldo MC, de Castro-Neto EF, de Almeida SS, Matas SLA, Bertolucci PHF, Naffah-Mazzacoratti MDG. Aging Clin Exp Res; 2023 Aug 10; 35(8):1741-1752. PubMed ID: 37264166 [Abstract] [Full Text] [Related]
5. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Spies PE, Slats D, Sjögren JM, Kremer BP, Verhey FR, Rikkert MG, Verbeek MM. Curr Alzheimer Res; 2010 Aug 10; 7(5):470-6. PubMed ID: 20043812 [Abstract] [Full Text] [Related]
6. Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer's Disease and Cognitively Healthy People. de Oliveira FF, Miraldo MC, de Castro-Neto EF, de Almeida SS, Matas SLA, Bertolucci PHF, Naffah-Mazzacoratti MDG. J Alzheimers Dis; 2021 Aug 10; 81(3):1295-1309. PubMed ID: 33935098 [Abstract] [Full Text] [Related]
7. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies. Bolsewig K, van Unnik AAJM, Blujdea ER, Gonzalez MC, Ashton NJ, Aarsland D, Zetterberg H, Padovani A, Bonanni L, Mollenhauer B, Schade S, Vandenberghe R, Poesen K, Kramberger MG, Paquet C, Bousiges O, Cretin B, Willemse EAJ, Teunissen CE, Lemstra AW, European-Dementia With Lewy Bodies (E-DLB) ConsortiumFrom the Department of Laboratory Medicine (K.B., E.R.B., E.A.J.W., C.E.T.) and Alzheimer Center Amsterdam (A.A.J.M.U., A.W.L.), Amsterdam UMC, the Netherlands; Department of Quality and Health Technology (M.C.G.), University of Stavanger; The Norwegian Centre for Movement Disorders (M.C.G.) and the Centre for Age-Related Medicine (M.C.G., N.J.A., D.A.), Stavanger University Hospital, Norway; Department of Psychiatry and Neurochemistry (N.J.A., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Old Age Psychiatry (N.J.A., D.A.), King's College London, United Kingdom; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; UK Dementia Research Institute at UCL (H.Z.), London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), Hong Kong, China; Wisconsin Alzheimer's Disease Research Center (H.Z.), University of Wisconsin School of Medicine and Public Health, Madison; Neurology Unit (A.P.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Medicine and Aging Sciences (L.B.), University G. d'Annunzio of Chieti-Pescara, Chieti, Italy; Department of Neurology (B.M.), University Medical Center Göttingen; Paracelsus-Elena-Klinik (B.M., S.S.), Germany; Department of Neurosciences (R.V., K.P.), KU Leuven, Belgium; Department of Neurology and Medical Faculty (M.G.K.), University Medical Center Ljubljana, Slovenia; Department of Neurobiology (M.G.K.), Karolinska Institutet, Huddinge, Sweden; Université de Paris Cité (C.P.), Centre de Neurologie Cognitive, Paris; Laboratory of Biochemistry and Molecular Biology (O.B.), University Hospital of Strasbourg; University of Strasbourg and CNRS (O.B., B.C.); Memory Resource and Research Centre (B.C.), University Hospital of Strasbourg, France; Department of Neurology (E.A.J.W.), Multiple Sclerosis Center; Research Center for Clinical Neuroimmunology and Neuroscience Basel (E.A.J.W.); and Departments of Biomedicine and Clinical Research (E.A.J.W.), University Hospital Basel and University of Basel, Switzerland.. Neurology; 2024 Jun 25; 102(12):e209418. PubMed ID: 38830138 [Abstract] [Full Text] [Related]
8. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. Sauvée M, DidierLaurent G, Latarche C, Escanyé MC, Olivier JL, Malaplate-Armand C. J Alzheimers Dis; 2014 Jun 25; 41(2):377-86. PubMed ID: 24614902 [Abstract] [Full Text] [Related]
9. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. Lemstra AW, de Beer MH, Teunissen CE, Schreuder C, Scheltens P, van der Flier WM, Sikkes SA. J Neurol Neurosurg Psychiatry; 2017 Feb 25; 88(2):113-118. PubMed ID: 27794030 [Abstract] [Full Text] [Related]
10. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, van der Flier WM, Teunissen CE, Mollenhauer B, Fladby T, Kramberger MG, Bonanni L, Lemstra AW, European DLB consortium. J Alzheimers Dis; 2016 Aug 18; 54(1):287-95. PubMed ID: 27567832 [Abstract] [Full Text] [Related]
11. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage. Bousiges O, Bombois S, Schraen S, Wallon D, Quillard MM, Gabelle A, Lehmann S, Paquet C, Amar-Bouaziz E, Magnin E, Miguet-Alfonsi C, Delbeuck X, Lavaux T, Anthony P, Philippi N, Blanc F, ePLM network and collaborators. J Neurol Neurosurg Psychiatry; 2018 May 18; 89(5):467-475. PubMed ID: 29321140 [Abstract] [Full Text] [Related]
12. Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementias. Baiardi S, Abu-Rumeileh S, Rossi M, Zenesini C, Bartoletti-Stella A, Polischi B, Capellari S, Parchi P. Ann Clin Transl Neurol; 2019 Feb 18; 6(2):263-273. PubMed ID: 30847359 [Abstract] [Full Text] [Related]
13. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH, Cogo-Moreira H, Rabin JS, Black SE, Swardfager W, Alzheimer's Disease Neuroimaging Initiative. J Neurosci; 2019 Sep 11; 39(37):7428-7437. PubMed ID: 31350262 [Abstract] [Full Text] [Related]
14. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative. JAMA Psychiatry; 2014 Oct 11; 71(10):1183-91. PubMed ID: 25162367 [Abstract] [Full Text] [Related]
15. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T. J Neurol Neurosurg Psychiatry; 2010 Jun 11; 81(6):608-10. PubMed ID: 20522869 [Abstract] [Full Text] [Related]
16. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E. J Neurol Neurosurg Psychiatry; 2010 Oct 11; 81(10):1080-6. PubMed ID: 20547614 [Abstract] [Full Text] [Related]
17. Alterations of CSF cystatin C levels and their correlations with CSF Αβ40 and Αβ42 levels in patients with Alzheimer's disease, dementia with lewy bodies and the atrophic form of general paresis. Zhong XM, Hou L, Luo XN, Shi HS, Hu GY, He HB, Chen XR, Zheng D, Zhang YF, Tan Y, Liu XJ, Mu N, Chen JP, Ning YP. PLoS One; 2013 Oct 11; 8(1):e55328. PubMed ID: 23383156 [Abstract] [Full Text] [Related]
18. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. Chiasserini D, Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S, De Roeck N, Tambasco N, Stoops E, Vanderstichele H, Engelborghs S, Mollenhauer B, Calabresi P, Parnetti L. Alzheimers Res Ther; 2017 Jul 28; 9(1):52. PubMed ID: 28750675 [Abstract] [Full Text] [Related]
19. Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias. Geng C, Tan L, Chen C. Brain Res; 2024 Jun 15; 1833():148881. PubMed ID: 38519009 [Abstract] [Full Text] [Related]
20. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P. Biol Psychiatry; 2008 Nov 15; 64(10):850-5. PubMed ID: 18395699 [Abstract] [Full Text] [Related] Page: [Next] [New Search]